Neumora Therapeutics Property, Plant & Equipment

The latest PP&E for NMRA is $320K as of June 2026. That compares with $620K in the prior-year period — down 47.9% year over year. Investors often review this figure alongside Neumora Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, NMRA's PP&E moved from $620K to $320K — a 47.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Neumora Therapeutics's operating scale or balance-sheet position.

A PP&E figure of $320K for NMRA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NMRA's PP&E ($320K), review year-over-year change from $620K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.